avoid [1:8 C to 25 C (>36 F to 77 F) for 72 hours Adacel-Polio [Canadian product]: Store under refrigeration of 2 C to 8 C (36 F to 46 F); stable for 72 hours at temperatures up to 25 C (77 F); do not freeze. Discard if frozen. Boostrix-Polio, Infanrix-IPV [Canadian products]: Store under refrigeration of 2 C to 8 C (36 F to 46 F); do not freeze. Discard if frozen. Drug Interactions Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy. Consider therapy modification Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation. Consider therapy modification Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Exceptions: Cytarabine (Liposomal). Consider therapy modification Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine: May diminish the therapeutic effect of Tetanus Toxoids Vaccines. Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine. Consider therapy modification Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated). Monitor therapy Adverse Reactions All serious adverse reactions must be reported to the US Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at https://vaers.hhs.gov/esub/index . In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018). Adverse events reported within 4 to 7 days of vaccination: >10%: Cardiovascular: Swelling of injected limb (arm circumference increase: 36% to 68%), swelling of injected limb (extensive, 2%) Central nervous system: Malaise (35%), drowsiness (19%), headache (16%) Gastrointestinal: Decreased appetite (16%) Local: Injection site: Pain at injection site (57% to 77%), erythema at injection site (37% to 59%), swelling (26% to 40%) Neuromuscular & skeletal: Myalgia (54%) Miscellaneous: Fever (6% to 16%)] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Diphtheria toxoid / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Drug Class Vaccine combinations Related Drugs vaccine combinations Boostrix (Tdap) , Twinrix , Adacel (Tdap) , Pediarix , Tenivac (Td) Poliomyelitis Prophylaxis Pediarix , Pentacel , poliovirus vaccine, inactivated , Ipol , Kinrix , Quadracel , More... Diphtheria Prophylaxis Boostrix (Tdap) , Adacel (Tdap) , Pediarix , Tenivac (Td) , Decavac (Td) , More... Pertussis Prophylaxis azithromycin , Zithromax , clarithromycin , Biaxin , Boostrix (Tdap) , More... 1 more conditions... tourists
commonly Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine as we speak
EmoticonEmoticon